Related Experiment Video
Updated: Feb 11, 2026
07:30
Assessing Insulin Clearance in Mice via In Situ Liver Perfusion
Published on: December 13, 2024
819
[Faster aspart insulin (FIASP®)]
1Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Sart Tilman, Liège, Belgique.
Revue Medicale De Liege
|April 21, 2018
Summary
Faster aspart (Fiasp®) offers improved postprandial glucose control in diabetes patients. This novel insulin formulation enhances glucose management without significantly increasing hypoglycemia risk.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Current rapid-acting insulins aim to mimic physiological insulin release.
- Faster aspart (Fiasp®) is a novel formulation of insulin aspart designed for more precise mimicry of prandial insulin secretion.
Purpose of the Study:
- To evaluate the pharmacokinetic and pharmacodynamic profiles of faster aspart compared to standard insulin aspart.
- To assess the efficacy and safety of faster aspart in improving glycemic control in patients with type 1 and type 2 diabetes.
Main Methods:
- Head-to-head comparison of faster aspart and insulin aspart in Phase 3 clinical trials.
- Pharmacokinetic and pharmacodynamic analyses, including post hoc analysis of pooled data from six trials in type 1 diabetes patients.
Main Results:
- Faster aspart demonstrated significantly reduced postprandial glucose increments in both type 1 and type 2 diabetes.
- Glycated hemoglobin (HbA1c) levels were significantly reduced in type 1 diabetes patients.
- Faster aspart showed earlier plasma insulin appearance and greater early exposure compared to insulin aspart, without a marked increase in hypoglycemia.
Conclusions:
- Faster aspart offers a beneficial pharmacokinetic and pharmacodynamic profile, improving postprandial glucose control.
- The novel formulation provides enhanced glycemic management in diabetic patients, with a favorable safety profile regarding hypoglycemia.
Related Concept Videos
01:05Insulin Secretory Vesicles
7.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
7.0K
01:28Insulin: The Receptor and Signaling Pathways
3.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
3.5K
01:27Insulin Formulations: Types and Delivery
794
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
794
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.5K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.5K
01:16Insulin: Dosing Regimen and Adverse Effects
832
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
832
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.6K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.6K